Salud financiera de hoja de balance de FluoGuide

Salud financiera controles de criterios 3/6

FluoGuide tiene un patrimonio de los accionistas total de DKK12.7M y una deuda total de DKK10.0M, lo que sitúa su ratio deuda-patrimonio en 78.6%. Sus activos y pasivos totales son DKK29.6M y DKK16.9M respectivamente.

Información clave

78.6%

Ratio deuda-patrimonio

kr.10.00m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	kr.21.67m
Patrimonio	kr.12.72m
Total pasivo	kr.16.89m
Activos totales	kr.29.61m

Actualizaciones recientes sobre salud financiera

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (DKK28.3M) de 96X superan a sus pasivos a corto plazo (DKK16.3M).

Pasivo a largo plazo: Los activos a corto plazo de 96X (DKK28.3M) superan a sus pasivos a largo plazo (DKK623.0K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 96X tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de 96X ha crecido de 0% a 78.6% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 96X tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: 96X tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 35.9% cada año

Salud financiera de hoja de balance de FluoGuide

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

FluoGuide A/S Ordinary Shares to Be Deleted from OTC Equity

Recent updates

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

No longer forecast to breakeven

FluoGuide A/S to Report Q2, 2024 Results on Aug 29, 2024

FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001

Forecast to breakeven in 2025

FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer

FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference

Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague

New minor risk - Profitability

Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer

FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer

Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer

FluoGuide A/S to Report Q3, 2023 Results on Nov 29, 2023

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Forecast to breakeven in 2024

FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer

Forecast to breakeven in 2024

FluoGuide A/S Releases Positive Interim Result of FG001 in Head and Neck Cancer

FluoGuide A/S, Annual General Meeting, Mar 21, 2023

Forecast to breakeven in 2024

FluoGuide A/S to Report Fiscal Year 2022 Results on Feb 28, 2023

FluoGuide A/S Enrolls First Patient in the Phase IIa Trial in Head and Neck Cancer

FluoGuide A/S Reaches Milestone with FG001 for Phase III Clinical Supply

FluoGuide A/S Releases Positive Interim Result of FG001-CT002

FluoGuide A/S Enrolls the First Patient in the Phase IIb Trial in Aggressive Brain Cancer

FluoGuide A/S Presents the Outstanding Clinical Data from the Completed Phase I/IIa Trial with FG001 in Patients with Aggressive Brain Cancer Undergoing Surgery, At the World Molecular Imaging Congress

FluoGuide A/S Ordinary Shares to Be Deleted from OTC Equity

FluoGuide A/S Receives Approval from the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Head and Neck Cancer

FluoGuide Announces CFO Changes

FluoGuide Receives Permission to Start Phase IIb Trial in Aggressive Brain Cancer

Fluoguide A/S Update on Fg001's Clinical Development

FluoGuide Submits a Clinical Trial Application (CTA) to the Danish Medicines Agency to Initiate Phase II Trial with FG001 in Head and Neck Cancer

FluoGuide Publish the Presentation of FG001 Results from the First Clinical Trial in Aggressive Brain Cancer

FluoGuide A/S Announces Positive Top Line Result from Ongoing Clinical Phase I/II Trial

FluoGuide Submits Clinical Trial Application to the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Lung Cancer

Fluoguide Proceeds to Seventh Dose Level with Fg001 in the Ongoing Clinical Phase I/II Trial Following Continued Improvement of Tumor Illumination with Increasing Doses

FluoGuide Announces Regulatory Approval from Swedish Authorities to Commence Phase II Clinical Trial with FG001 in Guiding Surgery of High Grade Glioma in Sweden

FluoGuide A/S Announces Publication of Promising Preclinical Data on FG001 Effect in Treatment of Cancer

FluoGuide A/S Announces Promising Preclinical Data with Fg002 Technology in Guiding Surgical Removal of Cancer

FluoGuide has Received Green Light to Proceed to the Next Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients Undergoing Surgical Treatment of High Grade Glioma

FluoGuide Receives Approval to Commence with FG001 in Evening Dosing in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera